1 Regimens are guided by the severity of symptoms, risk of exacerbations and the patient’s response. However, there is limited evidence on the best choice of combinations of medicines for COPD management. 1, 2, 4Ĭombining bronchodilators of different classes may improve efficacy and decrease risk of side effects compared with increasing the dose of a single bronchodilator. 3, 4Ĭonsider adding theophylline in patients with severe COPD for whom other treatments have failed to control symptoms adequately. There is some evidence to support triple therapy (LABA + LAMA + ICS) improving lung function and quality of life, but more studies are required. ≤ 50% predicted and two or more exacerbations requiring treatment in the previous year). Long-acting bronchodilators include beta-2 agonists (LABAs) or anticholinergics/muscarinic antagonists (LAMAs).Ĭombination therapy with an inhaled corticosteroid (ICS) and a LABA is indicated for patients who remain symptomatic after treatment with long-acting bronchodilators ( FEV 1 Pharmacological interventions typically involve starting treatment with a short-acting reliever (either a short-acting beta-2 receptor agonist or a short-acting anticholinergic/muscarinic receptor antagonist ) as needed for symptom relief, before adding maintenance therapy with one or Non-pharmacological interventions such as smoking cessation, weight control, exercise and pulmonary rehabilitation are an important part of COPD management at every stage. Management of stable COPD requires a stepwise approach.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |